Objective To investigate the clinical features and prognosis of childhood acute lymphoblastic leukemia (ALL) with CREBBP gene mutation. Methods A retrospective analysis was performed for the clinical data of 14 ALL children with CREBBP gene mutation who were admitted to Children's Hospital of the First Affiliated Hospital of Zhengzhou University from January 2016 to December 2023. Results The ALL patients with CREBBP gene mutation accounted for 1.5% (14/963) among all children diagnosed with ALL during the same period of time, among whom there were 4 boys (29%) and 10 girls (71%), with a median age of 4 years and 3.5 months. All children had an immunological type of B-cell ALL and concurrent mutations in other genes including NRAS, KRAS, ETV6, FLT3, PAX5, SH2B3, CDKN2A, and CDKN2B, and 4 children had karyotype abnormality. All 14 children received induction therapy with the VDLP regimen, with a complete remission (CR) rate of 79% (11/14) after the first course of treatment. Three children experienced bone marrow recurrence alone, with a recurrence rate of 21% (3/14), among whom 1 child achieved CR after blinatumomab therapy and 2 received bridging hematopoietic stem cell transplantation after chemotherapy for recurrence. Among the 14 children, 1 died due to treatment discontinuation and 13 achieved disease-free survival. The 5-year overall survival rate was 92%±7%, and the event-free survival rate was 73%±13%. Conclusions ALL with CREBBP gene mutation is more common in girls and has a low induction remission rate and a high recurrence rate, and it is often accompanied by other types of gene mutations and abnormal karyotypes. Most children with recurrence can achieve long-term survival after immunotherapy or hematopoietic stem cell transplantation.
Key words
Acute lymphoblastic leukemia /
CREBBP gene /
Karyotype /
Prognosis /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
1 Raetz EA, Bhojwani D, Devidas M, et al. Children's Oncology Group blueprint for research: acute lymphoblastic leukemia[J]. Pediatr Blood Cancer, 2023, 70Suppl 6(Suppl 6): e30585. PMID: 37489549. PMCID: PMC10687839. DOI: 10.1002/pbc.30585.
2 中华医学会儿科学分会血液学组, 《中华儿科杂志》编辑委员会. 儿童急性淋巴细胞白血病诊疗建议（第四次修订）[J]. 中华儿科杂志, 2014, 52(9): 641-644. PMID: 25476423. DOI: 10.3760/cma.j.issn.0578-1310.2014.09.001.
3 李晨, 刘炜, 王亚峰, 等. 单中心CCLG-ALL 2018方案治疗MLL基因重排阳性儿童急性淋巴细胞白血病的临床研究[J]. 中国癌症防治杂志, 2023, 15(6): 637-643. DOI: 10.3969/j.issn.1674-5671.2023.06.07.
4 阮永胜, 吴学东. 儿童急性淋巴细胞白血病复发的研究进展[J]. 中华临床医师杂志（电子版）, 2014(18): 3359-3363. DOI: 10.3877/cma.j.issn.1674-0785.2014.18.030.
5 Zhu Y, Wang Z, Li Y, et al. The role of CREBBP/EP300 and its therapeutic implications in hematological malignancies[J]. Cancers (Basel), 2023, 15(4): 1219. PMID: 36831561. PMCID: PMC9953837. DOI: 10.3390/cancers15041219.
6 Janczar S, Janczar K, Pastorczak A, et al. The role of histone protein modifications and mutations in histone modifiers in pediatric B-cell progenitor acute lymphoblastic leukemia[J]. Cancers (Basel), 2017, 9(1): 2. PMID: 28054944. PMCID: PMC5295773. DOI: 10.3390/cancers9010002.
7 Dixon ZA, Nicholson L, Zeppetzauer M, et al. CREBBP knockdown enhances RAS/RAF/MEK/ERK signaling in RAS pathway mutated acute lymphoblastic leukemia but does not modulate chemotherapeutic response[J]. Haematologica, 2017, 102(4): 736-745. PMID: 27979926. PMCID: PMC5395114. DOI: 10.3324/haematol.2016.145177.
8 Dutta R, Tiu B, Sakamoto KM. CBP/p300 acetyltransferase activity in hematologic malignancies[J]. Mol Genet Metab, 2016, 119(1-2): 37-43. PMID: 27380996. DOI: 10.1016/j.ymgme.2016.06.013.
9 Mullighan CG, Zhang J, Kasper LH, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia[J]. Nature, 2011, 471(7337): 235-239. PMID: 21390130. PMCID: PMC3076610. DOI: 10.1038/nature09727.
10 Waanders E, Gu Z, Dobson SM, et al. Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia[J]. Blood Cancer Discov, 2020, 1(1): 96-111. PMID: 32793890. PMCID: PMC7418874. DOI: 10.1158/0008-5472.BCD-19-0041.
11 郑湧智, 郑浩, 陈再生, 等. 二代测序技术检测儿童急性淋巴细胞白血病的基因突变谱及其预后意义[J]. 中华血液学杂志, 2022, 43(1): 19-25. PMID: 35231988. PMCID: PMC8980667. DOI: 10.3760/cma.j.issn.0253-2727.2022.01.005.
12 陈燕, 祁闪闪, 丁丽丽, 等. 儿童急性淋巴细胞白血病患者基因突变谱与预后相关性的临床研究[J]. 中国实验血液学杂志, 2023, 31(1): 17-24. DOI: 10.19746/j.cnki.issn1009-2137.2023.01.003.
13 Malinowska-Ozdowy K, Frech C, Sch?negger A, et al. KRAS and CREBBP mutations: a relapse-linked malicious liaison in childhood high hyperdiploid acute lymphoblastic leukemia[J]. Leukemia, 2015, 29(8): 1656-1667. PMID: 25917266. PMCID: PMC4530204. DOI: 10.1038/leu.2015.107.
14 Paulsson K, Lilljebj?rn H, Biloglav A, et al. The genomic landscape of high hyperdiploid childhood acute lymphoblastic leukemia[J]. Nat Genet, 2015, 47(6): 672-676. PMID: 25961940. DOI: 10.1038/ng.3301.
15 Inthal A, Zeitlhofer P, Zeginigg M, et al. CREBBP HAT domain mutations prevail in relapse cases of high hyperdiploid childhood acute lymphoblastic leukemia[J]. Leukemia, 2012, 26(8): 1797-1803. PMID: 22388726. PMCID: PMC4194312. DOI: 10.1038/leu.2012.60.
16 Tran TH, Hunger SP. The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities[J]. Semin Cancer Biol, 2022, 84: 144-152. PMID: 33197607. DOI: 10.1016/j.semcancer.2020.10.013.
17 Lu SX, Abdel-Wahab O. Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia[J]. Proc Natl Acad Sci U S A, 2016, 113(40): 11071-11073. PMID: 27663730. PMCID: PMC5056046. DOI: 10.1073/pnas.1613836113.
18 Gao C, Liu SG, Lu WT, et al. Downregulating CREBBP inhibits proliferation and cell cycle progression and induces daunorubicin resistance in leukemia cells[J]. Mol Med Rep, 2020, 22(4): 2905-2915. PMID: 32945392. PMCID: PMC7453649. DOI: 10.3892/mmr.2020.11347.
19 Li B, Brady SW, Ma X, et al. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia[J]. Blood, 2020, 135(1): 41-55. PMID: 31697823. PMCID: PMC6940198. DOI: 10.1182/blood.2019002220.
20 Gao C, Zhang RD, Liu SG, et al. Low CREBBP expression is associated with adverse long-term outcomes in paediatric acute lymphoblastic leukaemia[J]. Eur J Haematol, 2017, 99(2): 150-159. PMID: 28452416. DOI: 10.1111/ejh.12897.
21 李晓兰, 刘立鹏, 刘芳, 等. 贝林妥欧单抗治疗儿童复发/难治急性淋巴细胞白血病的安全性及近期疗效分析[J]. 中国当代儿科杂志, 2023, 25(4): 374-380. PMID: 37073842. PMCID: PMC10120344. DOI: 10.7499/j.issn.1008-8830.2210114.
PDF(576 KB)
